Table 1.
Patients treated with dendritic cell (DC)/tumour-fusion vaccine with or without a combination with recombinant human interleukin (rhIL)-12, and their serum levels of anti-nuclear antibody (ANA) before and after the treatments.
| Anti-nuclear antibody (OD) | ||||||
|---|---|---|---|---|---|---|
| Type of malignancy | Case, age, sex | Total DC (×106) | Total IL-12 (ng) | Treatment period (months) | Before treatment | After treatment |
| Gastric cancer | ||||||
| 1 (patient 1) | 74 years, M | 7·8 | 0 | 4 | 0·03 | 0·13 |
| 2 | 50 years, M | 7·0 | 0 | 6 | 0·1 | 0·07 |
| 3 | 61 years, F | 6·0 | 0 | 5 | 0·1 | 0·09 |
| Breast cancer | ||||||
| 1 | 32 years, F | 3·1 | 8 100 | 1·5 | 0·1 | 0·09 |
| 2 (patient 2) | 60 years, F | 21·8 | 0 | 24 | 0·04 | 0·12 |
| 3 | 54 years, F | 4·0 | 9 000 | 1·5 | 0·06 | 0·15 |
| Ovarian cancer | ||||||
| 1 (patient 3) | 65 years, F | 12·8 | 28 800 | 9 | 0·16 | 0·59 |
| 2 | 54 years, F | 20·7 | 52 104 | 9 | 0·26 | 0·27 |
| 3 | 58 years, F | 26·3 | 15 180 | 3 | 0·04 | 0·09 |
| 4 | 56 years, F | 9·6 | 11 340 | 2 | 0·06 | 0·04 |
| Colon cancer | ||||||
| 1 | 54 years, M | 3·7 | 8 916 | 8 | 0·09 | 0·09 |
| 2 | 31 years, F | 4·5 | 0 | 2 | 0·11 | 0·05 |
| 3 | 31 years, F | 3·1 | 19 965 | 2·5 | 0·14 | 0·1 |
| 4 | 62 years, M | 6 | 19 744 | 3 | 0·05 | 0·12 |
| Others | ||||||
| 1 | 35 years, F | 7·8 | 0 | 2 | 0·09 | 0·07 |
| 2 | 48 years, M | 5·5 | 0 | 1·5 | 0·07 | 0·09 |
| 3 | 54 years, M | 10·5 | 0 | 4 | 0·1 | 0·13 |
| 4 | 38 years, F | 6·8 | 0 | Unevaluable | 0·07 | 0·07 |
| 5 | 58 years, M | 8 | 0 | 3 | 0·07 | 0·06 |
| 6 | 59 years, M | 23 | 0 | 5 | 0·09 | 0·07 |
| 7 | 37 years, M | 18·2 | 0 | 5 | 0·05 | 0·04 |
| 8 | 45 years, M | 5·2 | 0 | 1·5 | 0·05 | 0·04 |
Others 1; pulmonary cancer, 2; oesophagial cancer, 3; hepatocellular carcinoma, 4; tongue cancer, 5; bladder cancer, 6; mesothelioma, 7; epithelioid sarcoma, 8; malignant histeocytosis.